Targeted inhibition of VEGF receptor 2: an update on ramucirumab

Bibliography

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 200;356(2):115-24
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011;146(6):873-87
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006;12(17):5018-22
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006;7(5):359-71
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 2011;108(28):11590-5
   PubMed Web of Science ®Google Scholar
• Hedlund EM, Yang X, Zhang Y, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 2013;110(2):654-9
   PubMed Web of Science ®Google Scholar
• Albrecht I, Kopfstein L, Strittmatter K, et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 2010;5(11):e14109
   PubMed Web of Science ®Google Scholar
• Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141(1):166-77
   PubMed Web of Science ®Google Scholar
• Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24(16):2647-53
   PubMed Web of Science ®Google Scholar
• Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001;97(3):785-91
   PubMed Web of Science ®Google Scholar
• Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002;417(6892):954-8
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2(10):1096-103
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87(8):3336-43
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350(7):672-83
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25(4):581-611
   PubMed Web of Science ®Google Scholar
• Ryden L, Linderholm B, Nielsen NH, et al. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 2003;82(3):147-54
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur J Clin Invest 2007;37(11):878-86
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Turley H, et al. Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol 2006;19(5):701-7
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10
   PubMed Web of Science ®Google Scholar
• Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012;5:63
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III Randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;
   Google Scholar
• Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III Trial. J Clin Oncol 2012;
   PubMed Web of Science ®Google Scholar
• Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (aflibercept) April 5, 2012
   Google Scholar
• Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued September 11, 2009
   Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6(10):569-79
   PubMed Web of Science ®Google Scholar
• Witte L, Hicklin DJ, Zhu Z, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17(2):155-61
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59(20):5209-18
   PubMed Web of Science ®Google Scholar
• Lu D, Shen J, Vil MD, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 2003;278(44):43496-507
   PubMed Web of Science ®Google Scholar
• Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. Biochem Biophys Res Commun 2006;345(1):438-45
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Franklin MC, Navarro EC, Wang Y, et al. The structural basis for the function of two anti-VEGF receptor 2 antibodies. Structure 2011;19(8):1097-107
   PubMed Web of Science ®Google Scholar
• Chiorean E SC, Hurwitz H, Savage S, et al. Phase I dose-escalation study of the anti-VEGFR-2recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers. 2007
   Google Scholar
• Spratlin J. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr Oncol Rep 2011;13(2):97-102
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Mulcahy MF, et al. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). ASCO Meeting Abstracts 2010;28(15_Suppl):4083
   Google Scholar
• Camidge DR, Ballas MS, Dubey S, et al. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2010;28(15_Suppl):7588
   Google Scholar
• Carvajal RD, Wong MK, Thompson JA, et al. A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM). ASCO Meeting Abstracts 2010;28(15_Suppl):8519
   Google Scholar
• Penson RT, Moore KN, Fleming GF, et al. A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162. ASCO Meeting Abstracts 2012;30(15_Suppl):5012
   Google Scholar
• Hussain M, Rathkopf DE, Liu G, et al. A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy. ASCO Meeting Abstracts 2012;30(5_Suppl):97
   Google Scholar
• Garcia-Carbonero R, Rivera F, Maurel J, et al. A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784. ASCO Meeting Abstracts 2012;30(4_Suppl):533
   Google Scholar
• Vahdat LT, Miller K, Sparano JA, et al. Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402). ASCO Meeting Abstracts 2011;29(15_Suppl):TPS151
   Google Scholar
• Petrylak DP, Chi KN, Vogelzang NJ, et al. Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy. ASCO Meeting Abstracts 2012;30(15_Suppl):TPS4675
   Google Scholar
• Fuchs CS, Tomasek J, Cho JY, et al. REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. ASCO Meeting Abstracts 2013;31(4_Suppl):LBA5
   Google Scholar
• Fuchs CS TJ, Cho JY, Filip D, et al. REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy. American Association for Cancer Research, Annual Meeting 2013; Washington DC; 2013
   Google Scholar
• Yi JH, Lee J, Park SH, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012;106(9):1469-74
   PubMed Web of Science ®Google Scholar
• Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28(18):2947-51
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968-76
   PubMed Web of Science ®Google Scholar
• Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011;47(15):2306-14
   PubMed Web of Science ®Google Scholar
• Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30(13):1513-18
   PubMed Web of Science ®Google Scholar
• Zhu AX, Chau I, Blanc J-F, et al. A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). ASCO Meeting Abstracts 2012;30(15_Suppl):TPS4146
   Google Scholar
• Full Prescribing Information: Stivarga. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf [ [Cited 2013 April 10]
   Google Scholar
• Full Prescribing Information: avastin. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s267lbl.pdf [Cited 2013 April 10]
   Google Scholar
• Full Prescribing Information: zaltrap. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125418s000lbl.pdf [Cited 2013 April 10]
   Google Scholar
• Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012;30(32):4026-34
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
   PubMed Web of Science ®Google Scholar
• Leppanen VM, Jeltsch M, Anisimov A, et al. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood 2011;117(5):1507-15
   PubMed Web of Science ®Google Scholar
• Lieu CH, Tran HT, Jiang Z, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. ASCO Meeting Abstracts 2011;29(15_Suppl):3533
   Google Scholar
• Nixon AB, Pang H, Starr M, et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. J Clin Oncol 2011;29(Suppl):abstract 10508
   Google Scholar
• Weickhardt AJ WD, Lee C, Simes J, et al. Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study. J Clin Oncol 2011;29(Suppl):abstract 3531
   Google Scholar
• Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92(11):4150-66
   PubMed Web of Science ®Google Scholar
• Osada T, Chong G, Tansik R, et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57(8):1115-24
   PubMed Web of Science ®Google Scholar
• Wu Y, Hooper AT, Zhong Z, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006;119(7):1519-29
   PubMed Web of Science ®Google Scholar